In a statement, Trotter described his experience as a child with older relatives who struggled with Type 2 diabetes. Trotter ...

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

The Food and Drug Administration has declared an end to the shortage of Novo Nordisk’s blockbuster ... sold under the brand names Ozempic for diabetes and Wegovy for obesity, had been on the ...

Shares of Novo Nordisk slipped in Monday morning trading ... trial to see how the drug compared to the company's other drugs, Ozempic, which is approved by the FDA for diabetes, and Wegovy ...

New York, USA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Novo Nordisk’s OZEMPIC Approval Heat Up the Chronic Kidney Disease Therapeutic Market | DelveInsight The FDA’s recent approval of OZEMPIC ...

The Food and Drug Administration on Friday said the shortage of Novo Nordisk's weight-loss and diabetes drugs Wegovy and Ozempic is resolved, a move that could limit the availability of cheaper ...

Pharmaceutical manufacturer Novo Nordisk on Wednesday announced it will ... recently confirming that both Wegovy and Ozempic, forms of the GLP-1 medication semaglutide, are no longer in shortage.

Novo Nordisk said Wednesday it will sell Wegovy for $499 a month in cash to patients who can’t get the blockbuster weight-loss drug through insurance, a bid to reach consumers who can’t afford ...